Provisional Anti-Dumping Measure on Chinese Glass Container Imports
Importers of the affected glass containers must guarantee the payment of the anti-dumping duty for a period of six months from the effective date.
Primary source: TGA Safety Alerts - Media releases feed
Changes to the Personal Importation Scheme were implemented, affecting how imported therapeutic goods are packaged and identified.
These changes could significantly impact local pharmacovigilance compliance efforts and improve the safety of therapeutic goods within Australia.
Review current compliance workflows and adjust processes for monitoring imports under the new packaging rules.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Review current compliance workflows and adjust processes for monitoring imports under the new packaging rules.
The Australian Government has updated the Personal Importation Scheme to aid authorities in identifying imported therapeutic goods and to minimize the risks of unidentified, mislabelled, or counterfeit products entering Australia.
What changed: Changes to the Personal Importation Scheme were implemented, affecting how imported therapeutic goods are packaged and identified.
Why it matters: These changes could significantly impact local pharmacovigilance compliance efforts and improve the safety of therapeutic goods within Australia.
Practical implication: Review current compliance workflows and adjust processes for monitoring imports under the new packaging rules.
Published from the regulator source ingestion pipeline after PV impact triage.
Importers of the affected glass containers must guarantee the payment of the anti-dumping duty for a period of six months from the effective date.
Monitor and possibly revise compliance reporting processes to reflect new regulatory expectations stemming from the fine imposed on United Utilities Limited.
Organizations must review and update compliance protocols in response to expanded trade prohibitions and prepare for restrictions on Iranian aviation effective immediately.
Stakeholders should prepare for discussions regarding veterinary medicinal product reviews, specifically focusing on maximum residue limits and ensure all interests are declared by participants.